مقالات پذیرفته شده در هفتمین کنگره بین المللی زیست پزشکی
Insight to mRNAs vaccine and effectiveness
Insight to mRNAs vaccine and effectiveness
zahra mohammadi,1Saman Hakimian,2,*
1. Bachelor of Microbiology university of shiraz campus 2. M.sc student of microbiology Islamic azad university central tehran branch.iran.tehran
Introduction: mRNA vaccines take advantage of the mechanism that our cells use to produce protein Our cells produce proteins based on the knowledge contained in our DNA; each gene encodes a unique protein. The genetic information is essential, but cells cannot use it until mRNA molecules convert it into instructions for producing specific proteins. mRNA vaccinations provide ready-to-use mRNA instructions for constructing a specific protein. BNT162b2(Pfizer-Biotech) and mRNA-1273( moderna) both are newly approved mRNA-based COVID-19 vaccines that have shown excellent protection and efficacy.
Methods: Lipid nanoparticle (LNP)-formulated messenger RNA (mRNA) vaccineare a promising platform to prevent infectious diseases as demonstrated by the recent success of SARS-CoV-2 mRNA vaccines. To avoid immune recognition and uncontrolled inflammation, nucleoside-modified mRNA in used.
. Our results show that partial substitution of ionizable lipidoid with adjuvant lipidoid not only enhanced mRNA delivery, but also endowed LNPs with Toll-like receptor
7/8agonistic activity, which significantly increased the innate immunity of the SARS-CoV-2 mRNA-LNP vaccine with good tolerability in mice.
To verify if adjuvant lipidoid substitution is a generally applicable start – egy to enhance the adaptive immune responses of mRNA-LNP vaccines,we further chose the approved SM-102 LNP formulation for investigation.
Results: Together, all the above results confirm that adjuvant lipidoid substitution can enhance the immunogenicity of clinically relevant SARS-CoV-2 mRNA-LNP vaccines, which holds translational potential.
Conclusion: The results of the above formula demonstrate that C12-TLRa substitution can increase antigen-specific antibody responses and B cell responses of clinically relevant mRNA-LNP vaccines.